Dawn Smilek, MD, PhD
Professor
Diabetes Center
School of Medicine

Publications (14)

Top publication keywords:
CyclophosphamideMicrobiotaAutoimmune DiseasesMultiple Sclerosis, Relapsing-RemittingImmune System DiseasesImmunotherapyAbataceptImmune ToleranceUstekinumabLupus NephritisT-Lymphocytes, RegulatoryPsoriasisQuantitative Trait LociImmunosuppressive AgentsRituximab

• Editorial: Innovative approaches to immune tolerance and regulation with gene, cellular, protein, and microbiome based therapeutics.
  Frontiers in immunology 2024 Rosenberg A, Smilek DE
• Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin.
  Nature communications 2023 Xiao Q, Mears J, Nathan A, Ishigaki K, Baglaenko Y, Lim N, Cooney LA, Harris KM, Anderson MS, Fox DA, Smilek DE, Krueger JG, Raychaudhuri S
• Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial.
  JAMA dermatology 2021 Harris KM, Smilek DE, Byron M, Lim N, Barry WT, McNamara J, Garcet S, Konrad RJ, Stengelin M, Bathala P, Korman NJ, Feldman SR, Boh EE, Barber K, Laumann AE, Helfrich YR, Krueger GG, Sofen H, …
• Approaches to Establishing Tolerance in Immune Mediated Diseases.
  Frontiers in immunology 2021 Huffaker MF, Sanda S, Chandran S, Chung SA, St Clair EW, Nepom GT, Smilek DE
• A CD8+ NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis.
  Nature communications 2021 McKinney EF, Cuthbertson I, Harris KM, Smilek DE, Connor C, Manferrari G, Carr EJ, Zamvil SS, Smith KGC

Show all (9 more) Hide

• Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
  Arthritis & rheumatology (Hoboken, N.J.) 2020 Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon…
• Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis.
  Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,…
• The immune cell landscape in kidneys of patients with lupus nephritis.
  Nature immunology 2019 Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P,…
• Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.
  Journal of immunology (Baltimore, Md. : 1950) 2019 Glatigny S, Höllbacher B, Motley SJ, Tan C, Hundhausen C, Buckner JH, Smilek D, Khoury SJ, Ding L, Qin T, Pardo J, Nepom GT, Turka LA, Harris KM, Campbell DJ, Bettelli E
• Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis.
  Lupus science & medicine 2017 Smilek DE, Lim N, Ding L, Murray SG, Diamond B, Wofsy D
• ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2016 Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE, ACCLAIM Study Group
• Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.
  Arthritis & rheumatology (Hoboken, N.J.) 2015 Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M
• Solving the puzzle of autoimmunity: critical questions.
  F1000prime reports 2015 Smilek DE, St Clair EW
• Restoring the balance: immunotherapeutic combinations for autoimmune disease.
  Disease models & mechanisms 2014 Smilek DE, Ehlers MR, Nepom GT